

NEW Active Substances

PRODUCT	THERAPEUTIC AREA	DOSAGE FORM	BRAND COMPANY	ASMF	PATENT EXPIRY	SPC
Abemaciclib	Oncology	Tablets	Eli Lilly	Q1/2025	2029	2033
Apalutamide	Oncology	Tablets	Janssen-Cilag	Yes	2027	2032
Avatrombopag	Antihemorrhagic	Tablets	SOBI	Q1/2025	Expired	2028
Cabozantinib	Oncology	Tablets	Ipsen	Yes	Expired	2029
Carfilzomib	Oncology	Powder for inj. solution	Amgen	Yes	Expired	2030
Edoxaban	Antithrombotic	Tablets	Daiichi Sankyo	Yes	Expired	2027
Empagliflozin	Diabetes	Tablets	Boehringer	Yes	2025	2029
Enzalutamide	Oncology	Soft capsules	Astellas	Yes	2026	2028
Finerenone	Cardiovascular/Diuretics	Tablets	Bayer	Q4/2024	2028	2033
Ibrutinib	Oncology	Hard capsules	Janssen-Cilag	Yes	2026	2029
Lenvatinib	Oncology	Hard capsules	Eisai	Yes	Expired	2027
Lotilaner	Anti-parasitic	Eye drops	Tarsus	Under dev.	2029	2032
Macitentan	Cardiovascular	Tablets	Actelion	Yes	Expired	2026
Nintedanib	Oncology	Soft capsules	Boehringer	Yes	Expired	2026
Nusinersen	Musculoskeletal	Vials	Biogen	Yes	2026	2031
Olaparib	Oncology	Hard capsules	AstraZeneca	Yes	Expired	2029
Palbociclib	Oncology	Hard capsules	Pfizer	Yes	Expired	2028
Pazopanib	Oncology	Tablets	Glaxo	Yes	Expired	2025
Perampanel	Epilepsy	Tablets	Eisai	Q1/2025	Expired	2026
Regorafenib	Oncology	Tablets	Bayer	Yes	Expired	2028
Ribociclib	Oncology	Tablets	Novartis	Yes	2029	2032
Rimegepant	Migraine	Tablets	Pfizer	Yes	2030	2035
Ruxolitinib	Oncology	Tablets	Novartis	Yes	2026	2028
Semaglutide	Diabetes	Pen	Novo Nordisk	Yes	2026	2031
Tirzepatide	Diabetes	Syringe/Pen	Lilly	Q2/2025	2036	2037
Tofacitinib	Oncology	Tablets	Pfizer	Yes	Expired	2027
Venetoclax	Oncology	Tablets	AbbVie	Yes	2030	2031
Vibegron	Urological	Tablets	Pierre Fabre	Yes	2029	Pending
Vortioxetine	CNS	Tablets/Drops	Lundbeck	Yes	Expired	2028

Further products available on request.

Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes a patent infringement.
 Status of the information: Q4-2025